Effect of Purgative Manna on Neonatal Hyperbilirubinemia: A Systematic Review and Meta-analysis

Firoozeh Sajedi and Shiva Fatollahierad*

Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Abstract

The aim of this systematic review was to evaluate the effect of purgative manna on the unconjugated hyperbilirubinemia in neonates. Pubmed, Scopus, Chochrane library, Iranmedex and Google scholar were last searched in February 2017. Randomized controlled trials that evaluated the effect of purgative manna on the treatment of neonatal hyperbilirubinemia were included in the review. For meta-analysis, weighted mean difference (WMD) with 95% confidence interval (CI) was used. The outcomes of interests were serum bilirubin levels and length of hospital stay in neonates with jaundice. Seven randomized controlled trials with 812 neonates were eligible to be included in this systematic review. The meta-analysis included six of seven controlled trials. Bilirubin levels were significantly lower at 12 h (WMD: -1.48, 95% CI: -2.31 to -0.65), 24 h (WMD: -2.47, 95% CI: -3.22 to -1.71), 36 h (WMD: -2.83, 95% CI: -4.87 to -0.80), 48 h (WMD: -1.49, 95% CI: -2.36 to -0.63) and 72 h (WMD: -0.68, 95% CI: -1.28 to -0.08) following intervention in purgative manna group. Length of hospital stay was also decreased in purgative manna group (WMD: -0.93, 95% CI: -1.35 to -0.50). Finally, purgative manna administration decreased serum bilirubin level and length of hospital stay in neonates with unconjugated hyperbilirubinemia. More studies are needed to evaluate the efficacy, dosage, and side effects of purgative manna.

Keywords: Purgative manna; Neonate; Hyperbilirubinemia; Management; Meta-analysis.

Introduction

Jaundice is one of the most common problems in neonates (1, 2). The prevalence of severe hyperbilirubinemia was 12 percent in the north of Iran in 2005 and 15 percent in the south of Iran in 2010 (3, 4). Neonatal hyperbilirubinemia is mostly benign but high serum bilirubin levels may cause kernicterus, brain damage, and consequently developmental delay (5-6).

Phototherapy is the conventional treatment method for neonatal hyperbilirubinemia in recent years; however, many infants need exchange transfusion (ET) if phototherapy could not reduce the total serum bilirubin level in them effectively. ET could cause morbidities such as necrotizing enterocolitis, acute renal failure, and even death in neonates (7). In addition, phototherapy itself might have side effects and can be harmful especially in extremely low-birth-weight (ELBW) newborns (8). Retinal degeneration, diarrhea, dehydration, skin rash (9), oxidative stress-related diseases such as necrotizing enterocolitis and patent ductus arteriosus are reported adverse effects of phototherapy (10).
Allergic diseases such as asthma and allergic rhinitis (11), nevi, apoptosis and DNA damage in peripheral blood lymphocytes of full-term infants (1) have been found to be higher with this treatment method.

As a result of these side effects, other treatment methods are studied to decrease the duration of phototherapy and reduce the chance of ET in neonates. Complementary medicine such as purgative manna administration in Iran was used for the treatment of neonatal jaundice before phototherapy became common practice (12).

Purgative manna is a white rather yellow sweet substance produced by an insect on Cotoneaster genus of Rosaceae Family which is called shirkhesht in Persian (13). The most substances in purgative manna are mannitol, fructose, glucose, and sucrose. About 40 to 60 percent of manna is mannitol (14).

The laxative effect of manna might interrupt bilirubin enterohepatic circulation and reduce indirect bilirubin. Several studies evaluated the effect of purgative manna on neonatal jaundice. They reported that manna could decrease the duration of phototherapy by reducing bilirubin levels in icterus neonates (15-17). Thus, we carried out this systematic review and meta-analysis to assess the effect of purgative manna in combination with phototherapy on the management of unconjugated hyperbilirubinemia in neonates.

Experimental

Methods

We searched Pubmed, Medline, Scopus, Cochrane library, Iranmedex, and Google scholar in February 2017 to identify all relevant and published studies about the effect of purgative manna on neonatal jaundice. The database searches were performed using the medical subject heading terms “purgative manna”, “hyperbilirubinemia”, “hyperbilirubinemia, neonatal”, “jaundice”, “jaundice, neonates” and key words “purgative manna”, “shirkhesht”, “shir khesht”, “bilineaster”, “cotoneaster”, “jaundice”, “hyperbilirubinemia”, “bilirubin”.

The reference lists of identified studies and review articles were also hand searched. The search of databases was not restricted by language.

The titles and abstracts of the relevant studies were assessed for eligibility. The studies appearing eligible based on their abstracts were read in full.

The studies were included if they were randomized controlled trials (RCT) and assessed the effect of purgative manna as a treatment method on unconjugated hyperbilirubinemia in neonates. Articles that evaluated the effect of purgative manna on prevention of neonatal hyperbilirubinemia or examined the effect of purgative manna in-vitro were excluded.

The following data were extracted from included studies by two of review authors: author, publication year, number of participants, characteristics of neonates (gestational age, birth weight, nutrition, postnatal age and total serum bilirubin level on hospital admission), dose of purgative manna, purgative manna sources, side effects of treatment and outcomes. The unstated details were obtained through communication with the authors of included studies.

Furthermore, the risk of bias of studies was evaluated independently by the two reviewers using “the Cochrane Collaborations’ tool for assessing risk of bias” (23). Therefore, the methods of randomization, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting were assessed for each study.

Each of the mentioned domain was assessed as ‘low risk of bias’, ‘high risk of bias’, or ‘unclear risk of bias’. Disagreements between the reviewers about the risk of bias for any domain were resolved by consensus.

The outcomes of interest were serum bilirubin levels at 12, 24, 36, 48, and 72 h after the start of intervention, the length of hospital stay, and the frequency of defecation per day in neonates.

We used Review Manager 5.3 (The Cochrane Collaboration) to do the meta-analysis and write the review.

The pooled effects of purgative manna on bilirubin levels were calculated as weighted mean difference (WMD) with 95% CI. WMD below zero suggests benefit to the intervention
groups (if confidence interval does not include the zero line) because bilirubin is expected to decrease with time. Fixed effects or random effects model was used for the meta-analysis according to the test of heterogeneity ($I^2$). If $I^2$ was less than 50, then the fixed effects model was employed. A $p$-value $< 0.05$ was considered statistically significant.

**Results**

A total of 165 articles from different databases were identified. After reviewing the full text of articles, only seven clinical trials with 812 neonates met the inclusion criteria and were included in this review (Figure 1). The languages of selected studies were in Persian.

![Figure 1. Flow diagram of study.](image-url)
Effect of Purgative Manna

The risk of bias of studies was evaluated by two authors. All seven trials were RCTs however three of them had used alternation as the method of randomization (16, 21-22) and only one study described the method of allocation concealment (20). The risk of bias summary and graph of included studies are summarized in Figures 2 and 3.

The dates of trials were from 1999 to 2017. Five of trials included only term infants (17, 19-22) and two of them included both term and preterm neonates (16, 18).

Neonates in six trials received purgative manna orally every eight hours. One of these six trials administered manna for only one day (19) and one trial administered manna for 48 h (20). In one study neonates just received manna for a single oral dose during the first hour of hospital admission (18). In addition, all neonates in the control and intervention groups of seven included trials received phototherapy on hospital admission and during hospitalization. The characteristics of included studies are presented in Table 1.

The preparation methods of purgative manna solution for neonates in included studies were as follows:

Fayazmoghaddam et al. dissolved one gram of purgative manna into 30 mL water for 10 neonates every day (33.33 mg purgative manna/mL). Afterwards, 20 cc of solution were administered to every neonate three times a day (16).

Azadbakht et al. obtained manna from Khorasran, a province of north eastern Iran.
They dissolved 400 g of *manna* into 400 mL of distilled water and dried it under reduced pressure. Propyl paraben and methyl paraben were used as preservative. Finally, the dry extract had 88.3% *manna* from which 50-60% was mannitol. One mL of the drop contained 610 mg active constituents based on mannitol (610 mg mannitol/mL). The neonates in intervention group received five drops of purgative manna solution three times a day (17).

Farhat et al. collected purgative manna from Khorasan. They dissolved six grams of *manna* into distilled water (8 mL) for every neonate (750 mg purgative manna/mL) (18).

Ghotbi et al. gathered purgative manna from Khorasan. They divided *manna* to five gram packages. Every package was for administration to one neonate for one day. Five grams of *manna* was dissolved into 30 mL boiling water every day (166.67 mg purgative manna/mL). Every neonate in intervention group received 10 mL of prepared solution three times a day for the duration of one day (19).

Fallah et al. (20) and Ameli et al. (22) used Bilineaster drop from Sobhan Darou Company (300 mg mannitol/mL) and Rafieian-Kopaei et al. (21) used Bilineaster drop from Barij Essence Pharmaceutical Company.

In three trials, the number of neonates who needed exchange transfusion or Phenobarbital were reported. Azadbakht et al. reported that three neonates in control group had exchange transfusion. In addition, Phenobarbital or purgative manna was administered to four neonates in control group to manage jaundice. None of the neonates in intervention group needed exchange transfusion or Phenobarbital (17). Furthermore, in Fallah et al. study one neonate in each group of trial required exchange transfusion (20). Ameli et al. also reported that one neonate in purgative manna group and five neonates in control group received Phenobarbital and eleven neonates in control group underwent phototherapy again after discharge for the management of their hyperbilirubinemia (22). The obtained results of trials are summarized in Table 2.

**Meta-analysis findings**

In meta-analysis, one study was not included because they administered purgative manna only for one dose (18) and the rest of studies administered *manna* three times a day. Thus, the intervention was very different from the rest of studies. Three trials had more than one intervention group. As a result, among 708 neonates in included studies of meta-analysis, only 618 neonates were considered for analysis and 90 neonates in intervention groups other than purgative manna were excluded.
Table 1. Characteristics of included studies.

| Author, year (reference) | Date and Location | Participants | TBS level on admission | Intervention | Purgative manna dose (mg) | Purgative manna source |
|--------------------------|-------------------|--------------|------------------------|--------------|--------------------------|------------------------|
| Fayazmoghaddam, 1999 (16) | October 1998, Sanandaj, Iran | 136 neonates | Admission on 24 h to 72 h after birth: 15-20 mg/dL. Admission on more than 72 h after birth: ≥20 mg/dL. | Intervention group (n = 68): Purgative manna three times a day + phototherapy. Control group (n = 68): water (placebo) three times a day + phototherapy. | 666.67 mg purgative manna three times a day | Not reported |
| Azadbakht, 2005 (17) | Iran | 200 neonates Full-term | Unclear | Intervention group (n = 100): 5 drop purgative manna three times a day + phototherapy. Control group (n = 100): placebo drop three times a day + phototherapy. | 152.5 mg mannitol three times a day | Manna of Cotoneaster discolor pojark from Qaien, Khorasan, Iran |
| Farhat, 2006 (18) | May 2001 to December 2003 Mashhad, Iran | 104 neonates Breastfed, more than 2500 g at birth | 18-29 mg/dL | Intervention group (n = 50): a single dose of 6 g of purgative manna dissolved into distilled water (8 mL) during the first hour of trial + phototherapy. Control group (n = 54): a single dose of starch solution (0.1%, 8 mL) colored with one drop of caramel solution (placebo) + phototherapy. | 6000 mg purgative manna for one dose | Manna of cotoneaster tricolor pojark from Qaien, Khorasan, Iran |
| Ghotbi, 2006 (19) | June 2003 to February 2006, Iran | 64 neonates Full-term, Breastfed, 2500-4000 g at birth, beginning of jaundice: 3-11 days after birth | 15-20 mg/dL | Intervention group (n = 32): 10 cc purgative manna three times a day for the duration of one day + phototherapy. Control group (n = 32): distilled water (placebo) three times a day + phototherapy. | 1666.67 mg purgative manna three times | Manna discolor from Khorasan |
| Author, year (reference) | Date and Location | Participants | TBS level on admission | Intervention | Purgative manna dose(mg) | Purgative manna source |
|-------------------------|-------------------|--------------|------------------------|--------------|----------------------------|------------------------|
| Fallah, 2014 (20)       | September 2012 to February 2013, Yazd, Iran | 90 neonates Full-term, breastfed, 2500-4000 g at birth, beginning of jaundice: 3-7 days after birth | 15-20 mg/dL | Intervention groups (n = 60): 1) Thirty neonates were given 5 drop per kg Bilineaster drop every 8 h up to 48 h + phototherapy 2) Thirty neonates received half of glycerin suppository every 12 h up to 48 h + phototherapy Control group (n = 30): phototherapy | 75 mg/kg Mannitol* three times a day | Bilineaster drop from Sobhan Darou Company |
| Rafieian-Kopaei, 2016 (21) | 2010, Shahrekord, Iran | 120 neonates Full-term, breastfed, 2500-4000 g at birth, beginning of jaundice: 2 days after birth | 14-20 mg/dL | Intervention groups (n = 90): 1) Thirty neonates were given 3 drop per kg Bilineaster drop three times a day + phototherapy and their mothers were given dose of neonates × 3 Bilineaster drop 2) Thirty mother were given dose of neonates × 3 Bilineaster drop 3) Thirty neonates were given 3 drop per kg Bilineaster drop three times a day + phototherapy Control group (n = 30): distilled water (placebo) three times a day + phototherapy | Unidentified | Bilineaster drop from Barij Essence Pharmaceutical Company |
| Ameli, 2017 (22)        | June 2015 to March 2016, Mashhad, Iran | 98 neonates Term (35-42 weeks), breastfed, more than 2000 g at birth, beginning of jaundice: 2-14 days after birth | More than 17-20 mg/dL | Intervention group (n = 49): 5 drop per kg Bilineaster drop three times a day + phototherapy Control group (n = 49): phototherapy | 75 mg/kg Mannitol* three times a day | Bilineaster drop from Sobhan Darou Company |

*The main constituent of manna is mannitol of which it may contain from 40 to 60 percent.
| Author, year (reference) | Outcomes | Results | Side effects in intervention group |
|-------------------------|----------|---------|-----------------------------------|
| Fayazmoghaddam, 1999 (16) | Length of hospital stay | Length of hospital stay were lower in intervention group ($p \leq 0.001$) | Not reported |
| Azadbakht, 2005 (17) | Bilirubin level, Length of hospital stay | Bilirubin levels were lower in intervention group at 12, 24, 36 and 72 h after treatment ($p \leq 0.05$). Discharge of the intervention group from hospital started after 1.5 days of hospitalization. For the control group, the beginning of release from hospital was after 2.5 days of hospitalization. | Small number of neonates developed listlessness caused by loss of water (as a result of osmotic diarrhea due to purgative manna or phototherapy) |
| Farhat, 2006 (18) | Bilirubin level, Defecation frequency | Bilirubin levels and defecation frequency of intervention group were not significantly different from control group | No side effects (follow up at 24 h after phototherapy discontinued) |
| Ghotbi, 2006 (19) | Bilirubin level, Length of hospital stay, Defecation frequency | Bilirubin levels were lower in intervention group at 12, 24 and 36 h after treatment ($p \leq 0.001$). Length of hospital stay was lower in intervention group ($p \leq 0.001$). Defecation frequency was significantly higher in intervention group ($p \leq 0.001$) | Small number of neonates developed listlessness caused by loss of water (as a result of osmotic diarrhea due to purgative manna or phototherapy) |
| Fallah, 2014 (20) | Bilirubin level, Length of hospital stay, Defecation frequency | Bilirubin levels were lower at 24 h ($p = 0.02$) and 48 h ($p = 0.02$) after treatment in purgative manna group. Length of hospital stay was lower in purgative manna group versus control group ($p = 0.02$). Defecation frequency was not significantly different between purgative manna group and control group | No side effects (during hospitalization and on the second day after discharge in the clinic of hospital, no side effects were seen in purgative manna group) |
| Rafieian-Kopaei, 2016 (21) | Bilirubin level, Length of hospital stay | Bilirubin levels were lower in intervention group at 12, 24 and 36 h after treatment ($p \leq 0.05$). Length of hospital stay was lower in intervention groups versus control group ($p \leq 0.001$) | No side effects |
| Ameli, 2017 (22) | Bilirubin level, Length of hospital stay | Bilirubin levels were lower at 24 h ($p < 0.001$) after treatment in purgative manna group. Length of hospital stay was lower in purgative manna group versus control group ($p < 0.001$) | No side effects (follow up one and two months after discharge by phone calls) |
Mean bilirubin level collected from neonates at 12 h after the start of intervention was lower for those allocated to purgative manna and phototherapy than placebo and phototherapy (5 trials, 482 neonates) (WMD: -1.48, 95% CI: -2.31 to -0.65). Since WMD show reduction of bilirubin with 1.48 and CI does not contain zero, the intervention is statistically significant (Figure 4). Similarly, five trials evaluating 479 neonates found significantly lower levels of neonatal bilirubin in purgative manna group at 24 h after the start of intervention (WMD: -2.47, 95% CI: -3.22 to -1.71) (Figure 5). At 36 h following intervention, four trials showed purgative manna group had lower level of bilirubin versus control one (351 neonates) (WMD: -2.83, 95% CI: -4.87 to -0.80) (Figure 6). In addition, four trials assessing neonatal bilirubin level at 48 h (276 neonates) (WMD: -1.49, 95% CI: -2.36 to -0.63) (Figure 7) and at 72 h after the onset of intervention, (2 trials, 129 neonates) (WMD: -0.68, 95% CI: -1.28 to -0.08) showed lower levels of bilirubin in purgative manna group (Figure 8).

Although six trials assessed the length of hospital stay in neonates but two of studies’ data were not available for quantitative analysis. In four studies, length of hospital stay was lower in purgative manna group versus control one (358 neonates) (WMD: -0.93, 95% CI: -1.35 to -0.50) (Figure 9) (16, 19, 20 and 22).

Defecation frequency was another outcome that was considered in two trials. Ghotbi et al. reported increasing number of defecation per day in intervention group (one trial) (64 neonates) (WMD: 0.71, 95% CI: 0.29 to 1.13) (19). However, Fallah et al. showed that number of defecation per day at 24 h (one trial) (60 neonates) (WMD: 0.65, 95% CI: -0.19 to 1.49) and 48 h (one trial) (60 neonates) (WMD: 1, 95% CI: 0.1 to 1.90) following intervention were not significantly different in both groups (20).

**Discussion**

We found that purgative manna administration reduced bilirubin levels at 12, 24, 36, 48, and 72 hours following treatment. In addition, our review revealed that purgative manna decreased the length of hospital stay and the duration of phototherapy. No significant side effects were seen in neonates during hospitalization and follow ups. The effect size of bilirubin level was more notable at 36 h (WMD: -2.83) compared with 12 and 24 h (WMD: -1.48 and -2.47 respectively). However, the effect size decreased at 48 h (WMD: -1.49) and 72 h (WMD: -0.68). This conclusion could be the result of lesser effect of treatment on lower blood bilirubin levels at 2 to 3 days after initiation of therapy and small number of still admitted neonates.

The majority of studies were incorporated just term infants without any hemolytic disorders. However, preterm infants are at increased risk of long exposure to phototherapy and its side effects. In addition, only in Fayazmoghaddam et al. and Farhat et al. studies, infants with a bilirubin level of more than 20 mg/dL were included (16, 18) and in the rest of studies the range of bilirubin level was 14 to 20 mg/dL on admission (19-22). Thus, more studies are needed to evaluate the efficacy of manna on preterm neonates and higher serum bilirubin levels in infants with jaundice.

Although the administration frequency of purgative manna was every eight hours in six studies, manna sources were not the same in them. The manna that was used in included studies, was from different companies or region. Thus their prepared drops might had different potency which leads to different results. Furthermore, based on the review, there were no serious side effects in neonates who received purgative manna during treatment but the majority of the studies didn’t evaluate infants in the following months of therapy. In respect to the importance of understanding any serious side effects of manna, long term follow up studies are needed. Hence we could not draw any precise conclusion about any adverse effects of manna.

We showed that length of hospital stay and consequently duration of phototherapy reduced significantly in intervention groups. This result is important since it can decrease any probable side effects of phototherapy. In addition, by staying less time in hospital, the cost of hospital stay and anxiety of parents will lessen.

Purgative manna might have laxative effect; therefore, it decreases bilirubin reabsorption by
### Effect of Purgative Manna

Comparison of bilirubin level at 36 h.

**Figure 6.** Comparison of bilirubin level at 36 h.

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Mean Difference | IV, Random, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|----------------|-------------------|
| Ameli 2017        | 11.7             | 2.34| 46    | 15.2         | 2.15| 49    | -21.6%         | -0.80 [-1.15, -0.20] |
| Azadbakht 2005    | 14.5             | 2.70| 100   | 16.9         | 2.40| 103   | -24.6%         | -2.49 [-3.11, -1.85] |
| Fallah 2014       | 15.07            | 1.96| 30    | 16.78        | 1.98| 39    | -20.7%         | -0.95 [-1.76, 0.18]  |
| Ghobi 2003        | 11.69            | 2.83| 32    | 13.98        | 2.32| 32    | 18.1%          | 2.07 [-3.45, -0.65]  |
| Rafieian-Kopaei 2019 | 13.17         | 2.31| 30    | 14.58        | 2.05| 39    | 17.4%          | -1.71 [-2.97, -0.48] |
| Total (95% CI)    | 241              |     | 241   | 100.0%       |     |       | -1.48 [-2.31, -0.65] |      |

Heterogeneity: $\tau^2 = 4.08$; $\chi^2 = 61.00$, df = 3 ($P < 0.00001$); $I^2 = 95$

Test for overall effect: $Z = 3.49$ ($P = 0.0001$)

---

Comparison of bilirubin level at 24 h.

**Figure 5.** Comparison of bilirubin level at 24 h.

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Mean Difference | IV, Random, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|----------------|-------------------|
| Ameli 2017        | 11.5             | 2.16| 49    | 12.9         | 2.32| 49    | 21.5%          | -1.40 [-2.29, -0.51] |
| Azadbakht 2005    | 12.8             | 2.60| 97    | 15.9         | 2.40| 100   | 24.2%          | -3.10 [-3.80, -2.40] |
| Fallah 2014       | 12.57            | 2.05| 30    | 14.36        | 2.26| 30    | 18.6%          | -1.79 [-2.88, -0.70] |
| Ghobi 2006        | 8.34             | 3.19| 32    | 11.66        | 2.33| 32    | 15.2%          | -3.32 [-4.69, -1.95] |
| Rafieian-Kopaei 2016 | 11.01         | 1.74| 30    | 13.82        | 2.03| 30    | 20.5%          | -2.81 [-3.77, -1.85] |
| Total (95% CI)    | 238              |     | 241   | 100.0%       |     |       | -2.47 [-3.22, -1.71] |      |

Heterogeneity: $\tau^2 = 0.48$; $\chi^2 = 9.46$, df = 3 ($P = 0.02$); $I^2 = 68$

Test for overall effect: $Z = 3.37$ ($P = 0.0001$)

---

Comparison of bilirubin level at 12 h.

**Figure 4.** Comparison of bilirubin level at 12 h.

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Mean Difference | IV, Random, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|----------------|-------------------|
| Ameli 2017        | 11.0             | 1.85| 34    | 10.7         | 1.62| 36    | 25.4%          | -0.50 [-1.32, 0.32] |
| Azadbakht 2005    | 12.2             | 2.30| 57    | 15           | 2.50| 100   | 25.5%          | -2.80 [-3.57, -2.03] |
| Ghobi 2006        | 3.9              | 2.48| 32    | 10.26        | 2.67| 32    | 24.0%          | -6.36 [-7.62, -5.10] |
| Rafieian-Kopaei 2016 | 11.14         | 1.47| 30    | 12.99        | 1.96| 30    | 25.2%          | -1.85 [-2.73, -0.97] |
| Total (95% CI)    | 153              |     | 198   | 100.0%       |     |       | -2.83 [-4.87, -0.80] |      |

Heterogeneity: $\tau^2 = 0.52$; $\chi^2 = 12.14$, df = 4 ($P = 0.02$); $I^2 = 67$

Test for overall effect: $Z = 6.02$ ($P < 0.00001$)

---

Comparison of bilirubin level at 36 h.

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Mean Difference | IV, Random, 95% CI |
|-------------------|------------------|----|-------|--------------|----|-------|----------------|-------------------|
| Ameli 2017        | 8.9              | 1.52| 14    | 9.6          | 1.49| 17    | 23.9%          | -0.70 [-1.77, 0.37] |
| Azadbakht 2005    | 11.9             | 2.29| 29    | 14.2         | 2.50| 96    | 27.0%          | -2.30 [-3.18, -1.42] |
| Fallah 2014       | 9.96             | 2.95| 30    | 12.27        | 2.40| 30    | 19.5%          | -2.31 [-3.87, -0.85] |
| Rafieian-Kopaei 2016 | 11.2           | 1.12| 30    | 12.06        | 1.71| 30    | 29.6%          | -0.66 [-1.59, -0.13] |
| Total (95% CI)    | 103              |     | 173   | 100.0%       |     |       | -1.49 [-2.36, -0.63] |      |

Heterogeneity: $\tau^2 = 0.52$; $\chi^2 = 9.46$, df = 3 ($P = 0.02$); $I^2 = 68$

Test for overall effect: $Z = 3.37$ ($P = 0.0007$)

---

Comparison of bilirubin level at 48 h.

**Figure 7.** Comparison of bilirubin level at 48 h.
the bilirubin level in management of neonatal hyperbilirubinemia. Although the administration frequency of purgative manna could reduce the bilirubin level in neonates and in consequence the duration of phototherapy. Thus, purgative manna could be used in combination with phototherapy to manage unconjugated hyperbilirubinemia in neonates. However, there is a need for more well designed studies to assess the efficacy, dosage, and any probable side effects of purgative manna.

The validity of drawing conclusions should be interpreted carefully. Small number of including participants in each outcome analysis is a weakness for this meta-analysis. Only 482 neonates at 12 h, 479 neonates at 24 h, 351 neonates at 36 h, 276 neonates at 48 h and 129 neonates at 72 h were compared between the efficacy of purgative manna and phototherapy treatment with phototherapy alone. In addition, six out of seven trials didn’t report the allocation concealment and just three studies were double blinded. Therefore, further well designed studies with larger sample sizes are needed to ascertain the actual efficacy of purgative manna for the management of neonatal hyperbilirubinemia.

In summary, oral administration of purgative manna could reduce the bilirubin level in neonates and in consequence the duration of phototherapy. Thus, purgative manna could be used in combination with phototherapy to manage unconjugated hyperbilirubinemia in neonates. However, there is a need for more well designed studies to assess the efficacy, dosage, and any probable side effects of purgative manna.

Acknowledgment

The authors are greatly indebted to Professor Nima Naderi (Editor-in-Chief) and anonymous reviewers for providing very useful comments and suggestions, which greatly improved the original manuscript of this paper. The authors wish to express their gratitude to Dr. Masoud Hajarian, without his comments and suggestions this paper would not have been possible.

The authors are also grateful to Dr. Marzieh

Figure 8. Comparison of bilirubin level at 72 h.

Figure 9. Comparison of length of hospital stay in days.
Parsaei and Atefeh Saber for their valuable comments.

References

(1) Yahia S, Shabaan AE, Gouida M, El-Ghanam D, Eldegl H, El-Bakary A and Abdel-Hady H. Influence of hyperbilirubinemia and phototherapy on markers of genotoxicity and apoptosis in full-term infants. *Eur. J. Pediatr.* (2015) 174: 459-64.
(2) Porter ML and Dennis BL. Hyperbilirubinemia in the term newborn. *Am. Fam. Physician* (2002) 65: 599-606.
(3) Mirfazeli A, Najafi L, Noohi AH and Cheraghali R. Investigation of caused of severe indirect hyperbilirubinemia in Gorgan. *J. Gorgan Univ. Med. Sci.* (2009) 11: 82-6.
(4) Najib Kh, Saki F, Hemmati F and Inaloo S. Incidence, risk factors and causes of severe neonatal hyperbilirubinemia in the south of Iran (Fars Province). *Iran. Red Crescent Med. J.* (2013) 15: 260-3.
(5) Dennergy PA, Seidman DS and Stevenson DK. Neonatal hyperbilirubinemia. *N. Engl. J. Med.* (2001) 344: 581-90.
(6) Sajedi F, Vameghi R, Mohseni-Bandpei MA, Alizad V, Hemmati S and Shahshahani S. Motor developmental delay in 7500 Iranian infants: Prevalence and risk factors. *Iran. J. Child Neurol.* (2009) 3: 43-50.
(7) Hakam N, Zenciroglu A, Aydin M, Okumus N, Dursun A and Dilli D. Exchange transfusion for neonatal hyperbilirubinemia: an 8 year single center experience in Turkey. *J. Matern. Fetal. Neonatal. Med.* (2015) 28: 1537-41.
(8) Arnold C, Pedroza C and Tyson JE. Phototherapy in ELBW newborns: does it work? Is it safe? The evidence from randomized clinical trials. *Semin. Perinatol.* (2014) 38: 452-64.
(9) Karakukcu C, Uştal M, Ozturk A, Baskol G and Saraymen R. Assessment of DNA damage and plasma catalase activity in healthy term hyperbilirubinemic infants receiving phototherapy. *Mutat. Res.* (2009) 680: 12-6.
(10) Gathwala G and Sharma S. Oxidative stress, phototherapy and the neonate. *Indian J. Pediatr.* (2000) 67: 805-8.
(11) Das RR and Naik SS. Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review. *Pediatr. Allergy Immunol.* (2015) 26: 2-11.
(12) Sina AA. *Ghanoon dar Teb.* Translated by Abdul Rahman Sharafkandi. 2nd ed. Soroush Publisher, Tehran (1989) 314.
(13) Fakhri M, Azadbakht M, Hamzeheghardeshti Z and Farhadi R. Purgative *manna* in Iran traditional medicine and new resources. *J. Islam. Iran. Tradit. Med.* (2016) 6: 347-53.
(14) Mirheydar H. *Herbal Information: Usage of Plants in Prevention and Treatment of Diseases.* 6th ed. Islamic Culture Press Center, Tehran, Iran (1992) 125-9.
(15) Khodashenas E, Khakshour A, Momeni E, Sinaei M and Mir M. Systematic review of herbal medicine efficacy on neonatal icterus. *J. North Khorasan Univ. Med. Sci.* (2016) 7: 683-9.
(16) Fayazmoghadam K, Reshadmanesh N and Kamali Sh. Study of the effect of *Manna* Ash on the management of neonatal Jaundice. *Sci. J. Kurlashan Univ. Med. Sci.* (1999) 4: 20-3.
(17) Azadbakht M, Pishva N, Mohammadi Samani S and Alinejad F. The Effect of Purgative Manna on the Infant Jaundice. *Iran. J. Pharm. Res.* (2005) 1: 95-100.
(18) Farhat A, Mohammadzadeh A, Ramezani M and Amiri M. The Effect of Shirkhesht on Newborns’ Indirect Hyperbilirubinemia. *Razi J. Med. Sci.* (2005) 12: 93-8.
(19) Ghotbi F, Nahidi S and Zangi M. Surveying the effect of cotoneaster spp. (shir khesht) on neonatal jaundice. *Res. Med.* (2006) 30: 353-61.
(20) Fallah R, Fallahzadeh MA and Noori-Shadkam M. Evaluation of safety and efficacy of purgative *manna* (billinaster drop) and glycerin suppository in icterus of healthy term newborns. *Curr. Drug Saf.* (2014) 9: 29-33.
(21) Rafieian-Kopaei M, Khoshdel A, Kheiri S and Shemian R. Cotoneaster: a safe and easy way to reduce neonatal jaundice. *J. Clin. Diagn. Res.* (2016) 10: SC01-3.
(22) Ameli Z, Assarroudi A and Akrami R. Effect of bilinaster drop on neonatal hyperbilirubinemia. *Evid. Based Care J.* (2017) 6: 66-73.
(23) Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group and Cochrane Statistical Methods Group. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. *BMJ* (2011) 343: d5928.

This article is available online at http://www.ijpr.ir